Illumina's Large Installed System Base Should Insulate It Somewhat From New Entrants
Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...
Illumina weakness ‘overdone,’ says Wolfe Research
Wolfe Research reiterated an Outperform rating and $150 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about ...
Roche SBX announcement creates more uncertainty for Illumina, says RBC
RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...